1. Home
  2. SLMT vs VERU Comparison

SLMT vs VERU Comparison

Compare SLMT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brera Holdings PLC Class B Ordinary Shares

SLMT

Brera Holdings PLC Class B Ordinary Shares

HOLD

Current Price

$3.99

Market Cap

39.1M

Sector

N/A

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.44

Market Cap

44.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLMT
VERU
Founded
2000
1971
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.1M
44.0M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
SLMT
VERU
Price
$3.99
$2.44
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
78.9K
200.4K
Earning Date
06-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$2.05
52 Week High
$24.05
$7.33

Technical Indicators

Market Signals
Indicator
SLMT
VERU
Relative Strength Index (RSI) 51.16 46.18
Support Level $3.63 $2.12
Resistance Level $4.60 $2.65
Average True Range (ATR) 0.33 0.10
MACD -0.01 -0.02
Stochastic Oscillator 69.20 30.39

Price Performance

Historical Comparison
SLMT
VERU

About SLMT Brera Holdings PLC Class B Ordinary Shares

Solmate Infrastructure Public Ltd is a Solana-based crypto infrastructure company with a strategic focus on Abu Dhabi. The group builds high-performance validators that lower latency, expand network reach, and position Abu Dhabi as a world-wide hub for Solana infrastructure. The company creates value by working with its partners to build infrastructure and real hardware for the crypto revolution. Its cutting-edge Solana staking infrastructure will help drive the adoption of the network in the Middle East.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: